N Engl J Med 2019 Dec 19
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Related Questions
What specific platforms for determining somatic BRCA and HRD status do you use for a patient who does not carry a germline BRCA mutation?
New comment by Medical Oncologist at Arizona Hem/Onc ( March 20, 2021)
Excellent review for practicing oncologists. Great information, both basic and applied.
New answer by at University of Pittsburgh (January 2, 2024)
To date, the clinical trials that have included biomarkers for response to PARP inhibitors have shown that those with BRCA pathogenic variants appear to have the largest benef...